Safety and Tolerability of Commonly Prescribed Oral Antibiotics for the Treatment of Respiratory Tract Infections

American Journal of Medicine

Volumn 123, Issue 4 SUPPL., 2010, Pages

  Lode, Hartmut ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Lactams; Antibacterial agents; Cephalosporins; Fluoroquinolones; Macrolides; Safety

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFALEXIN; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLOPIDOGREL; COTRIMOXAZOLE; DOXYCYCLINE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; IBUPROFEN; INSULIN; KETOLIDE; LEVOFLOXACIN; LINCOSAMIDE; LINEZOLID; MACROLIDE; METRONIDAZOLE; NAPROXEN; NITROFURAN DERIVATIVE; PARACETAMOL; PENICILLIN DERIVATIVE; PHENYTOIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN; WARFARIN;

ABDOMINAL PAIN; AGITATION; ALLERGIC REACTION; ANAPHYLAXIS; ANOREXIA; ANTIMICROBIAL THERAPY; ANUS PRURITUS; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; BEHAVIOR CHANGE; BLEEDING; BLOOD TOXICITY; CANDIDIASIS; CHOLESTASIS; CLINICAL TRIAL; COLITIS; CONFUSION; CONVULSION; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EMPYEMA; EOSINOPHILIA; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENITAL PRURITUS; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPOGLYCEMIA; INSOMNIA; LIVER FAILURE; LIVER TOXICITY; MENTAL DISEASE; MYALGIA; MYASTHENIA; NAUSEA; NEPHRITIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; OBSTRUCTIVE JAUNDICE; OUTPATIENT; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; QT PROLONGATION; RESPIRATORY TRACT INFECTION; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; SUPERINFECTION; SYNCOPE; TASTE DISORDER; TENDON INJURY; TENDON RUPTURE; THROMBOCYTOPENIA; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; VAGINITIS; VERTIGO; VOMITING;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEPHALOSPORINS; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; EMERGENCY SERVICE, HOSPITAL; EUROPEAN UNION; FLUOROQUINOLONES; GOVERNMENT AGENCIES; HUMANS; MACROLIDES; PRODUCT SURVEILLANCE, POSTMARKETING; RESPIRATORY TRACT INFECTIONS; SAFETY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77950294897     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2010.02.004     Document Type: Article

References (104)

1. Budnitz D.S., Pollock D.A., Weidenbach K.N., Mendelsohn A.B., Schroeder T.J., and Annest J.L. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296 (2006) 1858-1866
2. Shehab N., Patel P.R., Srinivasan A., and Budnitz D.S. Emergency department visits for antibiotic-associated adverse events. Clin Infect Dis 47 (2008) 735-743
3. Tulkens P, Van Bambeke F. Fluoroquinolone selection: appropriate benefit-risk profiles. Poster presented at the Fifth Forum on Respiratory Tract Infections; February 5, 2009; Barcelona, Spain.
4. Levine J.G., and Szarfman A. Data mining analysis of multiple antibiotics in AERS. http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4266s1-01-06-FDA-Levi ne.ppt Accessed May 26, 2009
5. Shlaes D.M., and Moellering R.C. Telithromycin and the FDA: implications for the future. Lancet Infect Dis 8 (2008) 83-85
6. Noel G.J. A review of levofloxacin for the treatment of bacterial infections. Clin Med Ther 1 (2009) 433-458
7. Kahn J.B. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 47 suppl 3 (2001) 32-37
8. Owens Jr. R.C., and Ambrose P.G. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 41 suppl 2 (2005) S144-S157
9. Khaliq Y., and Zhanel G.G. Fluoroquinolone-associated tendinopathy: a critical review of the literature. Clin Infect Dis 36 (2003) 1404-1410
10. Jagose J.T., McGregor D.R., Nind G.R., and Bailey R.R. Achilles tendon rupture due to ciprofloxacin. N Z Med J 109 (1996) 471-472
11. Casparian J.M., Luchi M., Moffat R.E., and Hinthorn D. Quinolones and tendon ruptures. South Med J 93 (2000) 488-491
12. van der Linden P.D., Sturkenboom M.C., Herings R.M., Leufkens H.G., and Stricker B.H. Fluoroquinolones and risk of Achilles tendon disorders: case-control study. BMJ 324 (2002) 1306-1307
13. Graumlich J.F., Habis S., Avelino R.R., et al. Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 25 (2005) 1296-1302
14. Park-Wyllie L.Y., Juurlink D.N., Kopp A., et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354 (2006) 1352-1361
15. Maeda N., Tamagawa T., Niki I., et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol 117 (1996) 372-376
16. Gajjar D.A., LaCreta F.P., Kollia G.D., et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 20 pt 2 (2000) 76S-86S
17. Van Bambeke F., and Tulkens P.M. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 32 (2009) 359-378
18. Zambon A., Polo F.H., Contiero P., and Corrao G. Effect of macrolide and fluoroquinolone antibacterials on the risk of ventricular arrhythmia and cardiac arrest: an observational study in Italy using case-control, case-crossover and case-time-control designs. Drug Saf 32 (2009) 159-167
19. Morganroth J., Dimarco J.P., Anzueto A., Niederman M.S., and Choudhri S. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 128 (2005) 3398-3406
20. Samaha F.F. QTc interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med 107 (1999) 528-529
21. Akita M., Shibazaki Y., Izumi M., et al. Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. J Toxicol Sci 29 (2004) 63-71
22. Avelox [prescribing information] (2008), Schering-Plough Corp, Kenilworth, NJ
23. Noel G.J., Natarajan J., Chien S., Hunt T.L., Goodman D.B., and Abels R. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther 73 (2003) 292-303
24. Tsikouris J.P., Peeters M.J., Cox C.D., Meyerrose G.E., and Seifert C.F. Effects of three fluoroquinolones on QT analysis after standard treatment courses. Ann Noninvasive Electrocardiol 11 (2006) 52-56
25. Adamantidis M.M., Dumotier B.M., Caron J.F., and Bordet R. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers. Fundam Clin Pharmacol 12 (1998) 70-76
26. Lode H. Evidence of different profiles of side effects and drug-drug interactions among the quinolones-the pharmacokinetic standpoint. Chemotherapy 47 suppl 3 (2001) 24-31
27. Bertino Jr. J., and Fish D. The safety profile of the fluoroquinolones. Clin Ther 22 (2000) 798-817
28. Noel G.J., Goodman D.B., Chien S., Solanki B., Padmanabhan M., and Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol 44 (2004) 464-473
29. Malik M., Hnatkova K., Schmidt A., and Smetana P. Electrocardiographic QTc changes due to moxifloxacin infusion. J Clin Pharmacol 49 (2009) 674-683
30. Ayalasomayajula S., Yeh C.M., Vaidyanathan S., et al. Effects of aliskiren, a direct renin inhibitor, on cardiac repolarization and conduction in healthy subjects. J Clin Pharmacol 48 (2008) 799-811
31. Iwamoto M., Kost J.T., Mistry G.C., et al. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol 48 (2008) 726-733
32. Davis J.D., Hackman F., Layton G., Higgins T., Sudworth D., and Weissgerber G. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects. Br J Clin Pharmacol 65 suppl 1 (2008) 68-75
33. Hulhoven R., Rosillon D., Bridson W.E., Meeus M.A., Salas E., and Stockis A. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. Clin Ther 30 (2008) 260-270
34. Koide T., Shiba M., Tanaka K., et al. Severe QT interval prolongation associated with moxifloxacin: a case report. Cases J 1 (2008) 409
35. Altin T., Ozcan O., Turhan S., et al. Torsade de pointes associated with moxifloxacin: a rare but potentially fatal adverse event. Can J Cardiol 23 (2007) 907-908
36. Dale K.M., Lertsburapa K., Kluger J., and White C.M. Moxifloxacin and torsade de pointes. Ann Pharmacother 41 (2007) 336-340
37. Fuhr U., Anders E.M., Mahr G., Sorgel F., and Staib A.H. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 36 (1992) 942-948
38. Zhang L., Wei M.J., Zhao C.Y., and Qi H.M. Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes. Acta Pharmacol Sin 29 (2008) 1507-1514
39. Granfors M.T., Backman J.T., Neuvonen M., and Neuvonen P.J. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 76 (2004) 598-606
40. Schmuck G., Schurmann A., and Schluter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 42 (1998) 1831-1836
41. Salvo F., Polimeni G., Cutroneo P.M., et al. Allergic reactions to oral drugs: a case/non-case study from an Italian spontaneous reporting database (GIF). Pharmacol Res 58 (2008) 202-207
42. Bartlett J.G., and Perl T.M. The new Clostridium difficile-what does it mean?. N Engl J Med 353 (2005) 2503-2505
43. Kelly C.P., and LaMont J.T. Clostridium difficile-more difficult than ever. N Engl J Med 359 (2008) 1932-1940
44. Muto C.A., Pokrywka M., Shutt K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 26 (2005) 273-280
45. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005) 2442-2449
46. Pépin J., Saheb N., Coulombe M.-A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41 (2005) 1254-1260
47. Spigaglia P., Barbanti F., Mastrantonio P., et al., for the European Study Group on Clostridium difficile (ESGCD). Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 57 (2008) 784-789
48. Klein J.O. History of macrolide use in pediatrics. Pediatr Infect Dis J 16 (1997) 427-431
49. Hopkins S. Clinical toleration and safety of azithromycin. Am J Med 91 (1991) 40S-45S
50. Whitman M.S., and Tunkel A.R. Azithromycin and clarithromycin: overview and comparison with erythromycin. Infect Control Hosp Epidemiol 13 (1992) 357-368
51. Guay D.R., Patterson D.R., Seipman N., and Craft J.C. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Saf 8 (1993) 350-364
52. Yanagihara K., Izumikawa K., Higa F., et al. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. Intern Med 48 (2009) 527-535
53. Paris R., Confalonieri M., Dal Negro R., et al. Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. J Chemother 20 (2008) 77-86
54. Kuzman I., Dakovic-Rode O., Oremus M., and Banaszak A.M. Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study. J Chemother 17 (2005) 636-642
55. Snyman J.R., Schoeman H.S., Grobusch M.P., et al. Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study. Clin Drug Investig 29 (2009) 265-274
56. Lee P.I., Wu M.H., Huang L.M., Chen J.M., and Lee C.Y. An open, randomized, comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia. J Microbiol Immunol Infect 41 (2008) 54-61
57. Bonvehi P., Weber K., Busman T., Shortridge D., and Notario G. Comparison of clarithromycin and amoxicillin/clavulanic acid for community-acquired pneumonia in an era of drug-resistant Streptococcus pneumoniae. Clin Drug Investig 23 (2003) 491-501
58. Tellier G., Niederman M.S., Nusrat R., Patel M., and Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 54 (2004) 515-523
59. Westphal J.F. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. Br J Clin Pharmacol 50 (2000) 285-295
60. Biaxin [prescribing information] (2008), Abbott Laboratories, North Chicago, IL
61. Saito H., Fukasawa Y., Otsubo Y., Yamada K., Sezaki H., and Yamashita S. Carrier-mediated transport of macrolide antimicrobial agents across Caco-2 cell monolayers. Pharm Res 17 (2000) 761-765
62. Kim R.B., Wandel C., Leake B., et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 16 (1999) 408-414
63. Siedlik P.H., Olson S.C., Yang B.B., and Stern R.H. Erythromycin coadministration increases plasma atorvastatin concentrations. J Clin Pharmacol 39 (1999) 501-504
64. Zuckerman J.M. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am 18 (2004) 621-649 xi
65. Guerriero S.E., Ehrenpreis E., and Gallagher K.L. Two cases of clarithromycin-induced digoxin toxicity. Pharmacotherapy 17 (1997) 1035-1037
66. Neu H.C., Wilson A.P., and Gruneberg R.N. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother 5 (1993) 67-93
67. Salvo F., De Sarro A., Caputi A.P., and Polimeni G. Amoxicillin and amoxicillin plus clavulanate: a safety review. Expert Opin Drug Saf 8 (2009) 111-118
68. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 (2005) 512-521
69. Garcia Rodriguez L.A., Stricker B.H., and Zimmerman H.J. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 156 (1996) 1327-1332
70. de Abajo F.J., Montero D., Madurga M., and Garcia Rodriguez L.A. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 58 (2004) 71-80
71. Larrey D., Vial T., Micaleff A., et al. Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut 33 (1992) 368-371
72. Lucena M.I., Andrade R.J., Fernandez M.C., et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology 44 (2006) 850-856
73. Salvo F., Polimeni G., Moretti U., et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother 60 (2007) 121-126
74. Martinez-Mir I., Ferrer J.M., Palop V., Estan L., Rubio E., and Morales-Olivas F.J. Are the adverse drug reactions of amoxycillin and amoxycillin-clavulanic acid similar?. Pharmacoepidemiol Drug Saf 5 (1996) 247-254
75. Naldi L., Conforti A., Venegoni M., et al. Cutaneous reactions to drugs: an analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 48 (1999) 839-846
76. Davydov L., Yermolnik M., and Cuni L.J. Warfarin and amoxicillin/clavulanate drug interaction. Ann Pharmacother 37 (2003) 367-370
77. Kelly M., Moran J., and Byrne S. Formation of rectus sheath hematoma with antibiotic use and warfarin therapy: a case report. Am J Geriatr Pharmacother 3 (2005) 266-269
78. Wood G.D., and Deeble T. Warfarin: dangers with antibiotics. Dent Update 20 (1993) 350 352-350, 353
79. Amoxil [prescribing information] (2008), GlaxoSmithKline, Research Triangle Park, NC
80. Easton J., Noble S., and Perry C.M. Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media. Drugs 63 (2003) 311-340
81. Turck D., Bernet J.P., Marx J., et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 37 (2003) 22-26
82. Mitropoulos I.F., Rotschafer J.C., and Rodvold K.A. Adverse events associated with the use of oral cephalosporins/cephems. Diagn Microbiol Infect Dis 57 suppl 3 (2007) 67S-76S
83. Fekety F.R. Safety of parenteral third-generation cephalosporins. Am J Med 88 (1990) 38S-44S
84. Neu H.C. Third generation cephalosporins: safety profiles after 10 years of clinical use. J Clin Pharmacol 30 (1990) 396-403
85. Bijie H., Kulpradist S., Manalaysay M., and Soebandrio A. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review. J Chemother 17 (2005) 3-24
86. Pichichero M.E., and Casey J.R. Safe use of selected cephalosporins in penicillin-allergic patients: a meta-analysis. Otolaryngol Head Neck Surg 136 (2007) 340-347
87. Fonacier L., Hirschberg R., and Gerson S. Adverse drug reactions to a cephalosporins in hospitalized patients with a history of penicillin allergy. Allergy Asthma Proc 26 (2005) 135-141
88. Suprax [prescribing information] (2003), Lupin Pharmaceuticals Inc, Baltimore, MD
89. Wu D.H. A review of the safety profile of cefixime. Clin Ther 15 (1993) 1108-1119
90. Gooch III W.M., Philips A., Rhoades R., Rosenberg R., Schaten R., and Starobin S. Comparison of the efficacy, safety and acceptability of cefixime and amoxicillin/clavulanate in acute otitis media. Pediatr Infect Dis J 16 suppl 2 (1997) S21-S24
91. Guay D.R. Cefdinir: an expanded-spectrum oral cephalosporin. Ann Pharmacother 34 (2000) 1469-1477
92. Guay D.R. Cefdinir: an advanced-generation, broad-spectrum oral cephalosporin. Clin Ther 24 (2002) 473-489
93. Neu H.C. Cephalosporins-cefotaxime 10 years later, a major drug with continued use. Infection 19 suppl 6 (1991) S309-S315
94. Goddard J.K., Janning S.W., Gass J.S., and Wilson R.F. Cefuroxime-induced acute renal failure. Pharmacotherapy 14 (1994) 488-491
95. Nahata M.C., and Barson W.J. Ceftriaxone: a third-generation cephalosporin. Drug Intell Clin Pharm 19 (1985) 900-906
96. Monte S.V., Prescott W.A., Johnson K.K., Kuhman L., and Paladino J.A. Safety of ceftriaxone sodium at extremes of age. Expert Opin Drug Saf 7 (2008) 515-523
97. Heim-Duthoy K.L., Caperton E.M., Pollock R., Matzke G.R., Enthoven D., and Peterson P.K. Apparent biliary pseudolithiasis during ceftriaxone therapy. Antimicrob Agents Chemother 34 (1990) 1146-1149
98. Grossjohann B., Eichler P., Greinacher A., Santoso S., and Kroll H. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells. Transfusion 44 (2004) 1033-1040
99. Chonmaitree T., Congeni B.L., Munoz J., Rakusan T.A., Powell K.R., and Box Q.T. Twice daily ceftriaxone therapy for serious bacterial infections in children. J Antimicrob Chemother 13 (1984) 511-516
100. Committee for Proprietary Medicinal Products (CPMP). European Agency for the Evaluation of Medicinal Products (EMEA). [EMEA Website.] Note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections. London: EMEA; April 22, 2004. http://www.emea.europa.eu/pdfs/human/ewp/055895en.pdf Accessed April 23, 2009
101. US Food and Drug Administration. MedWatch: the FDA Safety Information and Adverse Event Reporting Program. [FDA Web site.]. http://www.fda.gov/Safety/MedWatch/default.htm Accessed November 2, 2009
102. US Food and Drug Administration. Adverse Event Reporting System (AERS). [FDA Web site.]. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveil lance/AdverseDrugEffects/default.htm Accessed April 23, 2009
103. US Food and Drug Administration. Information for healthcare professionals: fluoroquinolone antimicrobial drugs [ciprofloxacin (marketed as Cipro and generic ciprofloxacin), ciprofloxacin extended release (marketed as Cipro XR and Proquin XR), gemifloxacin (marketed as Factive), levofloxacin (marketed as Levaquin), moxifloxacin (marketed as Avelox), norfloxacin (marketed as Noroxin), and ofloxacin (marketed as Floxin)] [FDA alert]. [FDA Web site.]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa tientsandProviders/ucm126085.htm Accessed June 23, 2009
104. US Food and Drug Administration. Telithromycin (marketed as Ketek) information. [FDA Web site.]. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa tientsandProviders/ucm107824.htm Accessed June 23, 2009